SQI Diagnostics Inc. is a healthcare company that operates in the medical diagnostics and research industry. SQI Diagnostics specializes in providing rapid diagnostic solutions to examine health conditions and recommend medicinal insights to patients. SQI Diagnostics Inc. is a publicly listed company on the Toronto Venture Stock Exchange, with its common shares listed under the ticker symbol SQD. In addition to the TSXV, the life sciences and diagnostics company lists and trades its common shares on the OTCQB Market (in the United States) under the stock symbol SQIDF.
The Toronto-based precision medicine company innovates, develops, markets and sells rapid diagnostic testing devices to patients, health professionals and consumers. The company commercializes proprietary technology and product solutions to run multiplex diagnostic tests to count or measure proteins, antibodies, inflammatory biomarkers and other molecules. The company works on diagnosis tests in ISO 13485:2016 and GLP certified laboratories.
SQI Diagnostics has developed COVID-19 testing solutions which are at the clinical development phase -- COVID-19 HOME Antibody Test Kit, RALI-fast™ COVID-19 Severity Triage POC Test, RALI-Dx™ COVID-19 Severity Triage Lab Test.
These solutions enable proper health management of people across hospitals, emergency departments, urgent care centers, clinics, organizations, schools, communities, and the consumer sector. The COVID-19 testing tools are awaiting approval from the Food and Drug Administration (FDA) for emergency use authorization. These products are not yet authorized by Health Canada.
SQI Diagnostics is planning to launch home testing Solutions, which includes direct-to-consumer products which will allow consumers to quickly diagnose health problems at home or office and take remedial medicines to maintain their health.
The company is working on the development of an advanced diagnostic solution -- the TORdx™ LUNG Test -- that assesses the health conditions of donor lungs on the basis of quantitative metrics for successful lung transplantation.
Additionally, SQI Diagnostics runs customized diagnostics and provides life science and research data to biopharmaceutical companies. The company is focusing its work on organ transplantation, autoimmune diseases, and serological testing.
SQI Diagnostics has operations in North America, including the United States and Canada, Europe and other geographies across the world. The company earns a significant part of its revenue from the market in the United States.